Oncology

Recommend
Email
Print

Fig A: This graph shows minimal difference between overall survival rates for people with osteosarcoma when treated with MAP chemotherapy (methotrexate, doxorubin and cisplatin) versus receiving MAP plus interferon therapy.

Oncology

Featured Research

Interferon Shows No Benefit in EURAMOS-1 Trial

Adding pegylated interferon to post-surgery maintenance therapy for people with osteosarcoma showed no clear benefit beyond existing standard chemotherapy, according to recent findings from the ongoing EURAMOS-1 clinical trial.

Click to view members

Research and Training Details

Faculty	28
Joint Appointment Faculty	3
Research Fellows and Post Docs	4
Research Graduate Students	7
Total Annual Grant Award Dollars	$2,566,350
Total Annual Industry Award Dollars	$2,587,017
Total Publications	58

Clinical Activities and Training

Staff Physicians	8
Clinical Fellows	3
Inpatient Encounters	11,508
Outpatient Encounters	17,393

Download Report in PDF Format
Visit Oncology

Oncology

Oncology

Oncology

Featured Research

Interferon Shows No Benefit in EURAMOS-1 Trial

Research and Training Details

Clinical Activities and Training

About Children's

Your Children's

Find Children's